Lisa Colleran - Establishment Labs Independent Director
| ESTA Stock | USD 49.69 1.42 2.94% |
Director
Ms. Lisa N. Colleran is Independent Director of the Company., since November 2015. She served as Global President of LifeCell Corporation from August 2008 to January 2012 after the company was acquired by Kinetic Concepts, Inc. In January 2012, Ms. Colleran was appointed Chief Executive Officer and Director of LifeCell Corporationrationration, a position she held until April 2013. Ms. Colleran originally joined LifeCell in 2002 as the Vice President of Marketing and Business Development and later served as Senior Vice President of Commercial Operations. Prior to joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare Corporation in various sales, marketing, business development and general management roles with international experience. She was appointed Vice President, Marketing for Baxter U.S. Renal business in 1997 and served in that role until 2001 when she was promoted to Vice PresidentGeneral Manager of the company Renal Pharmaceuticals business since 2015.
| Age | 60 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | Building B15 and 25, Alajuela, Costa Rica |
| Phone | 506 2434 2400 |
| Web | https://www.establishmentlabs.com |
Establishment Labs Management Efficiency
The company has return on total asset (ROA) of (0.1694) % which means that it has lost $0.1694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.3775) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.29. At present, Establishment Labs' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 4.9 M, whereas Total Assets are forecasted to decline to about 150.6 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Leavitt | HealthEquity | 66 | |
| Michael Shmerling | HealthStream | 62 | |
| Harald Arnet | National Research Corp | N/A | |
| Dale Polley | HealthStream | 67 | |
| Ian Sacks | HealthEquity | 47 | |
| Brita Eilertsen | National Research Corp | 53 | |
| Manu Rana | HealthEquity | 45 | |
| Barbara Mowry | National Research Corp | 70 | |
| Martiny Harris | HealthStream | 59 | |
| Linda Rebrovick | HealthStream | 62 | |
| P Shastri | National Research Corp | 65 | |
| Frank Gordon | HealthStream | 55 | |
| Frank Corvino | HealthEquity | 68 | |
| Evelyn Dilsaver | HealthEquity | 62 | |
| Martin Harris | HealthStream | 61 | |
| Debra McCowan | HealthEquity | 46 | |
| Thompson Dent | HealthStream | 68 | |
| Donald Berwick | National Research Corp | 71 | |
| Gayle Wellborn | HealthEquity | 56 | |
| Jeffrey McLaren | HealthStream | 51 | |
| Savita Acharya | National Research Corp | 41 | |
Management Performance
| Return On Equity | -15.38 | ||||
| Return On Asset | -0.17 |
Establishment Labs Leadership Team
Elected by the shareholders, the Establishment Labs' board of directors comprises two types of representatives: Establishment Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Establishment. The board's role is to monitor Establishment Labs' management team and ensure that shareholders' interests are well served. Establishment Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Establishment Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Hung, Independent Director | ||
| Lisa Gersh, Independent Director | ||
| Juan Quiros, CEO, Director | ||
| Heather Brennan, Head Operations | ||
| Nicholas Lewin, Independent Director | ||
| Roberto Mezerville, Chief Officer | ||
| Lisa Colleran, Independent Director | ||
| Paul Rodio, Chief Officer | ||
| Renee Gaeta, CFO | ||
| Dennis Condon, Independent Director | ||
| Salvador Santos, COO | ||
| Jeremy Livianu, General Counsel | ||
| Alberto Quesada, Vice President Quality & OUS Regulatory Affairs | ||
| Edward Schutter, Independent Director | ||
| Allan Weinstein, Independent Director | ||
| Ivan Bilic, Senior OUS | ||
| Eddie Oliveira, Vice President of Sales, Brazil | ||
| Ross Mansbach, General Officer | ||
| Jeffrey Bettinger, Global People | ||
| Neeta Toprani, Corporate Secretary | ||
| Rosalyn dIncelli, Medical Clinical | ||
| Rajbir Denhoy, Chief Officer | ||
| Salvador Dada, Chief Officer | ||
| Elizabeth Newman, VP Unit |
Establishment Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Establishment Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.38 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 1.47 B | ||||
| Shares Outstanding | 27.46 M | ||||
| Shares Owned By Insiders | 12.30 % | ||||
| Shares Owned By Institutions | 78.54 % | ||||
| Number Of Shares Shorted | 4.93 M | ||||
| Price To Earning | (20.11) X |
Pair Trading with Establishment Labs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Establishment Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Establishment Labs will appreciate offsetting losses from the drop in the long position's value.Moving against Establishment Stock
| 0.89 | SIBN | Si Bone Financial Report 6th of May 2024 | PairCorr |
| 0.87 | SRDX | SurModics Earnings Call This Week | PairCorr |
| 0.82 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.81 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
| 0.78 | DH | Definitive Healthcare Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Establishment Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Establishment Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Establishment Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Establishment Labs Holdings to buy it.
The correlation of Establishment Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Establishment Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Establishment Labs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Establishment Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Establishment Labs Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Establishment Stock analysis
When running Establishment Labs' price analysis, check to measure Establishment Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Establishment Labs is operating at the current time. Most of Establishment Labs' value examination focuses on studying past and present price action to predict the probability of Establishment Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Establishment Labs' price. Additionally, you may evaluate how the addition of Establishment Labs to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Establishment Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. If investors know Establishment will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Establishment Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.07) | Revenue Per Share 6.451 | Quarterly Revenue Growth (0.28) | Return On Assets (0.17) | Return On Equity (15.38) |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Establishment Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Establishment Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Establishment Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.